Tyra Biosciences (TYRA) Chief Discovery Officer sells shares under 10b5-1 plan

Rhea-AI Filing Summary

Tyra Biosciences, Inc. Chief Discovery Officer Daniel Bensen reported planned stock sales. On February 12, 2026, he completed two open-market sales of Tyra Biosciences common stock under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2024.

Bensen sold 2,128 shares at a weighted average price of $31.5018, with actual prices ranging from $31.02 to $31.75, and 5,872 shares at a weighted average price of $33.3666, with actual prices between $32.98 and $33.85. Following these transactions, he directly owned 146,981 shares of Tyra Biosciences common stock.

Insider Trade Summary

Net Seller: 8,000 shares ($262,965)

Net Sell 2 txns

Insider Bensen Daniel

Role Chief Discovery Officer

Sold 8,000 shs ($263K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,128	$31.5018	$67K
Sale	Common Stock	5,872	$33.3666	$196K

Holdings After Transaction: Common Stock — 152,853 shares (Direct)

Footnotes (1)

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $31.02 to $31.75. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $32.98 to $33.85. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bensen Daniel

(Last) (First) (Middle)

C/O TYRA BIOSCIENCES, INC.

2656 STATE STREET

(Street)

CARLSBAD CA 92008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tyra Biosciences, Inc. [ TYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Discovery Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		S(1)		2,128	D	$31.5018(2)	152,853	D
Common Stock	02/12/2026		S(1)		5,872	D	$33.3666(3)	146,981	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $31.02 to $31.75. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $32.98 to $33.85. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

	/s/ Ali D. Fawaz, Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Daniel Bensen report at Tyra Biosciences (TYRA)?

Daniel Bensen, Chief Discovery Officer of Tyra Biosciences, reported two open-market sales of common stock on February 12, 2026, totaling 8,000 shares. These trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2024, and were directly owned transactions.

How many Tyra Biosciences (TYRA) shares did Daniel Bensen sell and at what prices?

On February 12, 2026, Daniel Bensen sold 2,128 Tyra Biosciences shares at a weighted average price of $31.5018 and 5,872 shares at a weighted average price of $33.3666. The filing notes detailed price ranges for each trade and offers breakdowns from the issuer upon request.

How many Tyra Biosciences (TYRA) shares does Daniel Bensen hold after the reported sales?

After the February 12, 2026 transactions, Daniel Bensen directly owned 146,981 shares of Tyra Biosciences common stock. The Form 4 indicates these are non-derivative holdings, reflecting his remaining direct equity stake following the reported open-market sales executed under his Rule 10b5-1 plan.

Were Daniel Bensen’s Tyra Biosciences (TYRA) stock sales pre-planned under a Rule 10b5-1 plan?

Yes. The filing states that the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Daniel Bensen on November 5, 2024. Such plans pre-schedule trades, helping insiders systematically diversify while adhering to securities regulations.

What price ranges applied to Daniel Bensen’s Tyra Biosciences (TYRA) share sales?

For the 2,128 shares sold, the actual prices ranged from $31.02 to $31.75, with a weighted average of $31.5018. For the 5,872 shares, prices ranged from $32.98 to $33.85, with a weighted average of $33.3666. Detailed breakdowns are available from the issuer upon request.

What role does Daniel Bensen hold at Tyra Biosciences (TYRA) in this Form 4?

In this Form 4, Daniel Bensen is identified as an officer of Tyra Biosciences, serving as Chief Discovery Officer. The reported transactions involve his directly owned common stock, reflecting insider activity associated with a senior scientific leadership role at the company.